Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced second quarter 2025 results and held its first conference call under its new name. As we look ahead to the remainder of 2025, we expect ...

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical ...

CompletedstrategicpivotfromR&Dfocustocommercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and ...

Good evening and welcome to the Dyadic International's Q2 2024 Conference Call. Currently, all participants are in a listen-only mode. Following the management's prepared remarks, there will be a ...

Dyadic International, Inc. has announced a leadership change, appointing Joe Hazelton as President to enhance its strategy of focusing on ancillary recombinant protein products for life sciences, ...

Dyadic International and Cygnus Technologies formed a strategic partnership for the quantification of host cell proteins (HCPs) from the filamentous fungus Thermothelomyces heterothallica C-1 cells.

Good evening, and welcome to Dyadic International's Q3 2025 Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, November 12, 2025. I would now like to ...